The FDA has greenlit the first-ever human clinical trial of an ibogaine derivative in the United States, approving the testing of the psychedelic drug as a potential treatment for alcohol-use disorder. The move follows President Donald Trump’s executive order aimed at fast-tracking psychedelic research. FDA Commissioner Marty Makary stated that “these medications have the potential to address the nation’s mental health crisis” and that their development must be “grounded in sound science and rigorous clinical evidence.”
Ibogaine is a naturally occurring psychoactive compound found in the root bark of the iboga shrub, native to Central and West Africa. Tribal communities have used it for centuries in religious, spiritual, and healing ceremonies. In France, it was sold as a stimulant and antidepressant for more than three decades until the government banned it in the 1960s. Researchers began investigating its potential anti-addictive effects after anecdotal reports from heroin users claimed it reduced cravings and eased withdrawal symptoms.
Once ingested—typically in capsule form or powdered root bark mixed with water—ibogaine triggers long-lasting psychedelic and dissociative effects. Users initially describe a dream-like “trip” with vivid visions, followed by a deeply introspective phase lasting hours or days. Dr. Kirsten Cherian, a researcher at Stanford University who led a landmark study on ibogaine, noted that “it acts across multiple neurotransmitter systems” and its effects are “more intense than other psychedelics,” contributing to “reorganizing brain networks.”
A 2017 study administered a 12 mg/kg dose of ibogaine to 30 participants with opioid dependence. One month after treatment, half reported no opioid use; at the 12-month mark, seven had continued staying off drugs. Another study found 80% of people treated in Mexico reported eliminated or sharply reduced withdrawal symptoms, with 30% never using opioids again. Ibogaine has also shown potential benefits for depression, anxiety, and traumatic brain injuries.
However, ibogaine carries risks, including low blood pressure, seizures, difficulty breathing, anxiety, and hallucinations. It has been linked to more than 30 deaths in medical literature and causes irregular heart rhythms. Schedule I classification in the U.S. since 1967 has severely limited research. The FDA’s first-approved trial will test noribogaine hydrochloride, an ibogaine derivative developed by DemeRx NB. More than 29 million people in the U.S. are affected by alcohol use disorder.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://nypost.com/2026/04/25/health/what-is-ibogaine-fda-clears-first-human-trial-of-psychdelic/